August 16, 2017 The authors concluded: ‘Perifosine + lenalidomide + dexamethasone was well tolerated and demonstrated encouraging medical activity in relapsed and relapsed/refractory multiple myeloma’. Juergen Engel, PhD, President and CEO of Aeterna Zentaris stated, ‘Results of this study including the new exploratory pharmacodynamic data are among the reasons which encouraged us to continue our Phase 3 study with perifosine in multiple myeloma.’.. Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma Aeterna Zentaris Inc. The article outlines the safety profile and encouraging medical activity of perifosine when combined with dexamethasone and lenalidomide in relapsed and relapsed/refractory multiple myeloma.It really is based on a unique electro-optical hardware that allows measuring the spectral image of a metaphase, previously stained, in a way that each chromosome class has a different color . As the staining scheme of mFISH can be similar, HiSKY’s measurement scheme is very different than the main one utilized in mFISH, which is basically standard FISH acquisition done using multiple microscope filters. Allowing cytogeneticists intuitively discover chromosomal abnormalities they might not need discovered otherwise.